

GLAXOSMITHKLINE PLC

Form 6-K

October 10, 2018

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending 10 October 2018

GlaxoSmithKline plc

(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS

(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Ms E Walmsley
Chief Executive Officer
 - b) Position/status
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

Price(s)	Volume(s)
£14.749	9 (partnership shares)
£14.749	9 (matching shares)
 - d) Aggregated information

Aggregated volume	18 Ordinary Shares
Price	£14.749
 - e) Date of the transaction 2018-10-09
 - f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr R G Connor
 - b) Position/status President, Global Vaccines
 - c) Initial notification/
amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £14.749 9 (partnership shares) £14.749 9 (matching shares)
d) Aggregated information	18 Ordinary Shares
Aggregated volume Price	£14.749
e) Date of the transaction	2018-10-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr S Dingemans
b) Position/status	Chief Financial Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	Ordinary shares of 25 pence each ('Ordinary Shares')
a) Description of the financial instrument	ISIN: GB0009252882
b) Nature of the transaction	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
c) Price(s) and volume(s)	Price(s) Volume(s) £14.749 9 (partnership shares) £14.749 9 (matching shares)
d) Aggregated information	18 Ordinary Shares
Aggregated volume Price	£14.749
e) Date of the transaction	2018-10-09
f) Place of the transaction	London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr N Hirons
 - b) Position/status SVP, Global Ethics & Compliance
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 - b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
 - c) Price(s) and volume(s)

	Price(s)	Volume(s)
	£14.749	9 (partnership shares)
	£14.749	9 (matching shares)
 - d) Aggregated information

Aggregated information	18 Ordinary Shares
Aggregated volume Price	£14.749
 - e) Date of the transaction 2018-10-09
 - f) Place of the transaction London Stock Exchange (XLON)

1. Details of PDMR/person closely associated with them ('PCA')
 - a) Name Mr L Miels
 - b) Position/status President, Global Pharmaceuticals
 - c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
 - a) Name GlaxoSmithKline plc
 - b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
 - a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£14.749 9 (partnership shares) £14.749 9 (matching shares)
	Aggregated information
d) Aggregated volume Price	18 Ordinary Shares £14.749
e) Date of the transaction	2018-10-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	
a) Name	Mr D S Redfern
b) Position/status	Chief Strategy Officer
c) Initial notification/ amendment	Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a) Name	GlaxoSmithKline plc
b) LEI	5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted	Ordinary shares of 25 pence each (‘Ordinary Shares’) ISIN: GB0009252882
a) Description of the financial instrument	
	Acquisition of Ordinary Shares under the Company's Share Reward Plan.
b) Nature of the transaction	
	Price(s) Volume(s)
c) Price(s) and volume(s)	£14.749 9 (partnership shares) £14.749 9 (matching shares)
	Aggregated information
d) Aggregated volume Price	18 Ordinary Shares £14.749
e) Date of the transaction	2018-10-09
f) Place of the transaction	London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')	

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- a) Name Mr R Simard
 b) Position/status President, Pharmaceutical Supply Chain
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
 £14.749 8 (partnership shares)
 £14.749 8 (matching shares)
- d) Aggregated information 16 Ordinary Shares
 Aggregated volume Price £14.749
- e) Date of the transaction 2018-10-09
 f) Place of the transaction London Stock Exchange (XLON)
1. Details of PDMR/person closely associated with them ('PCA')
- a) Name Ms C Thomas
 b) Position/status SVP, Human Resources
 c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
 b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
 ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share

Reward Plan.

- | | | |
|---|--|------------------------|
| | Price(s) | Volume(s) |
| c) Price(s) and volume(s) | £14.749 | 9 (partnership shares) |
| | £14.749 | 9 (matching shares) |
| | | |
| d) Aggregated information | 18 Ordinary Shares | |
| Aggregated volume Price | £14.749 | |
| | | |
| e) Date of the transaction | 2018-10-09 | |
| f) Place of the transaction | London Stock Exchange
(XLON) | |
| | | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mr P C Thomson | |
| b) Position/status | President, Global Affairs | |
| c) Initial notification/
amendment | Initial notification | |
| | | |
| 2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | | |
| a) Name | GlaxoSmithKline plc | |
| b) LEI | 5493000HZTVUYLO1D793 | |
| | | |
| 3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | | |
| a) Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882 | |
| | | |
| b) Nature of the transaction | Acquisition of Ordinary Shares under the Company's Share Reward Plan. | |
| | | |
| | Price(s) | Volume(s) |
| c) Price(s) and volume(s) | £14.749 | 9 (partnership shares) |
| | £14.749 | 9 (matching shares) |
| | | |
| d) Aggregated information | 18 Ordinary Shares | |
| Aggregated volume Price | £14.749 | |
| | | |
| e) Date of the transaction | 2018-10-09 | |
| f) Place of the transaction | London Stock Exchange
(XLON) | |
| | | |
| 1. Details of PDMR/person closely associated with them ('PCA') | | |
| a) Name | Mrs V A Whyte | |
| b) Position/status | Company Secretary | |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

- c) Initial notification/ amendment Initial notification
2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
- a) Name GlaxoSmithKline plc
- b) LEI 5493000HZTVUYLO1D793
3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
- a) Description of the financial instrument Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
- b) Nature of the transaction Acquisition of Ordinary Shares under the Company's Share Reward Plan.
- c) Price(s) and volume(s) Price(s) Volume(s)
£14.749 9 (partnership shares)
£14.749 9 (matching shares)
- d) Aggregated information 18 Ordinary Shares
Aggregated volume Price £14.749
- e) Date of the transaction 2018-10-09
- f) Place of the transaction London Stock Exchange (XLON)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: October 10, 2018

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc